Jonathan Adam Feldschuh
Known title: Chief Scientific OfficerCIK: 0001701998
Associated companies
Transaction History
| DXR | ▲ Buy | Grant | 25,000 | $0 | 6/23/2026 | View on chart |
| DXR | ▲ Buy | Open Market | 18,000 | $0 | 12/9/2025 | View on chart |
| DXR | ▲ Buy | Open Market | 32,000 | $0 | 12/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026
Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026. Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.